EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer

Harun Taş iD, Martin Schäfer, Aneeba Shuja-Uddin, Ulrike Bauder-Wüst, Luciana Kovacs Dos Santos, Lisa Bartnitzky, Felix Oden, Magdalena Platzk, Tim König, Patrick Leopold Rüther iD, Elisabeth Pook iD, Kateřina Dvořáková Bendová und 4 weitere

Molecular Pharmaceutics · 06.04.2026 · 23 (4) · 2720-2734

DOI: 10.1021/acs.molpharmaceut.5c01853 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 03.03.2026. Verfasst von Harun Taş und 15 weiteren Autor:innen. Beteiligte Einrichtung: Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Kisspeptins, Receptors, Kisspeptin-1, Radiopharmaceuticals. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bayer, Deutsches Krebsforschungszentrum, Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsKisspeptinsReceptors, Kisspeptin-1RadiopharmaceuticalsHumansFemaleAnimalsLigandsCell Line, TumorRadioisotopesCricetulusLutetiumCHO CellsHeterocyclic Compounds, 1-RingMolecular Imaging

Stichwörter der Autor:innen

GPR54KISS1 receptorkisspeptinradiotheranosticstargeted radionuclide therapy (TRT)triple-negative breast cancer (TNBC)

Substanzen

KisspeptinsReceptors, Kisspeptin-1LigandsKISS1R protein, humanRadiopharmaceuticalsRadioisotopesLutetiumHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Research Group Translational Radiotheranostics, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
  • Service Unit for Radiopharmaceuticals and Preclinical Studies, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg 69120, Germany.
  • Bayer AG, Berlin 13342, Germany.
  • Bayer AG, Wuppertal 42113, Germany.
  • Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc 77900, Czech Republic.
  • Czech Advanced Technology and Research Institute, Palacký University, Olomouc 77900, Czech Republic.

ORCID-Profile: Harun Taş, Patrick Leopold Rüther, Elisabeth Pook, Miloš Petřík, Martina Benešová-Schäfer

Förderung

  • Bayer
  • Deutsches Krebsforschungszentrum
  • Ministerstvo ?kolstv?, Ml?de?e a Telov?chovy

Zitieren

APA

Taş, H., Schäfer, M., Shuja-Uddin, A., Bauder-Wüst, U., Kovacs Dos Santos, L., Bartnitzky, L., Oden, F., Platzk, M., König, T., Rüther, P. L., Pook, E., Dvořáková Bendová, K., Nový, Z., Petřík, M., Hagemann, U. B., & Benešová-Schäfer, M. (2026). Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics, 23(4), 2720-2734. https://doi.org/10.1021/acs.molpharmaceut.5c01853

Vancouver

Taş H, Schäfer M, Shuja-Uddin A, Bauder-Wüst U, Kovacs Dos Santos L, Bartnitzky L, et al. Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2026;23(4):2720-2734. doi:10.1021/acs.molpharmaceut.5c01853

BibTeX
@article{Ta2026,
  author = {Taş, Harun and Schäfer, Martin and Shuja-Uddin, Aneeba and Bauder-Wüst, Ulrike and Kovacs Dos Santos, Luciana and Bartnitzky, Lisa and Oden, Felix and Platzk, Magdalena and König, Tim and Rüther, Patrick Leopold and Pook, Elisabeth and Dvořáková Bendová, Kateřina and Nový, Zbyněk and Petřík, Miloš and Hagemann, Urs B and Benešová-Schäfer, Martina},
  title = {Investigation of Radiolabeled KISS1R Ligands as Promising Tools for Diagnosis and Treatment of Triple-Negative Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {4},
  pages = {2720--2734},
  doi = {10.1021/acs.molpharmaceut.5c01853}
}
Kostenlos starten →